Last December, we discussed how the snack bar company, Kind LLC, was first slammed by FDA for using “healthy” on its label and its fight to convince FDA to use current nutritional standards. This week, FDA reversed its decision and allowed the company to use “healthy” label on its packaging in relation to its “corporate philosophy,” not as a … Read more
Over the last few years, FDA has implemented several new pathways to expedite patient access to new drugs, biologics and medical devices. These programs, such as breakthrough designation, Fast Track review, Expedited Access Pathway and Priority Review, have significantly reduced the development and review time for new products. Faster approval adds more pressure on FDA to conduct … Read more
We hear occasionally about research articles that have been retracted due to faulty data or fraud. However, we seldom hear about overall impact of retracted articles. First, a given article may stay in publications for some time before it is retracted during which time it may be cited by others. Even after retraction of the article at … Read more
When we hear about data integrity issues these days, the obvious perception is of a facility in India or another foreign country getting caught trying to manipulate results. However, for a change (pun intended) this week we are talking about Theranos, a diagnostic lab in California with branches in Arizona and New Jersey, with serious data … Read more
This week FDA’s Advisory Committee (Ad Com) voted to reject Sarepta Therapeutics’ new drug for Duchenne Muscular Dystrophy (DMD) despite emotional pleas from patient groups and physicians in support of the drug. DMD treatments are eligible for most of FDA’s expedited approval pathways such as orphan drug designation, fast track designation, priority review status, and breakthrough designation. Sarepta had … Read more
This week, the Seattle-based gene therapy company, BioViva, made a bold claim to have invented the world’s first “successful” gene therapy for aging. The evidence for efficacy and safety of its product was generated in a manner that raises serious concerns of ethics, good scientific practices, and regulatory oversight. What is clearly a publicity stunt may … Read more
Almost every week FDA make public announcements about dietary supplements with risky ingredients such as unapproved drugs, hidden drug ingredients, dangerous chemicals and other ingredients. FDA’s web-site lists more than 700 such dietary supplements that are sold in the US market. The list is published based on tests conducted at FDA’s labs. However, very few retailers and distributors of … Read more
Data integrity issues have plagued manufacturing sites in India for several years. Repeatedly GMP sites in India were found in violation of documentation practices, data manipulation, data omission, and other issues that raise major issues about reliability of data. Although sites in India are not alone in data integrity issues but arguably sites in India received … Read more
A recent report based on a survey of about 1200 physicians provides a critique on how little prescribers know about the process of drug approval by the FDA. According to the report about 90% of the physicians surveyed could not correctly answer all three questions asked about FDA approval process. The survey asked two sets of questions; … Read more
It is well known that the most challenging aspect of running a given clinical trial is finding patients to participate in it. The main reasons are negative public perception of clinical trial participation, poorly designed clinical protocols and lack of planning by the clinical trial managers. And regulators are trying to help change that. Last … Read more
